8-K: PowerUp Acquisition Corp. Secures $184,543.80 Loan from Blackstone to Advance Aspire Biopharma Merger

PowerUp Acquisition Corp. has entered into a loan agreement with Blackstone Capital Advisors, Inc. for up to $500,000, with an initial draw of $184,543.80, to support its merger with Aspire Biopharma.

Summary

• PowerUp Acquisition Corp. has secured a loan agreement with Blackstone Capital Advisors, Inc., an entity controlled by Aspire Biopharma's Director of Investor Relations, Lance Friedman.
• The agreement allows for a loan of up to $500,000, with an initial principal amount of $184,543.80 already drawn.
• The loan has a 20% original issue discount, meaning the company receives less than the face value of the loan.
• The promissory note matures on the earlier of June 1, 2025, or when the company raises at least $5,000,000 in debt or equity.
• The loan bears a 10% annual interest rate, with interest and a 10% exit fee due at maturity.
• Upon the closing of the Business Combination, the Sponsor will transfer three Class A ordinary shares of PowerUp to Blackstone for each dollar loaned.
• PowerUp has also agreed to register these shares with the SEC.
• The loan is intended to support the company's efforts to complete its merger with Aspire Biopharma.

Sentiment

Score: 4

Explanation: The document reveals a necessary but expensive loan, indicating financial strain and a reliance on a potentially risky merger. The high cost of the loan and the potential dilution of shares are concerning, leading to a negative sentiment.

Positives

• The loan provides PowerUp with necessary capital to continue its operations and pursue the merger with Aspire Biopharma.
• The registration rights agreement ensures that Blackstone can potentially liquidate its investment in the future.
• The loan agreement includes customary terms and conditions, suggesting a standard financial arrangement.

Negatives

• The 20% original issue discount reduces the actual amount of capital received by PowerUp.
• The 10% exit fee increases the overall cost of the loan.
• The loan is secured by a transfer of shares to Blackstone upon the closing of the Business Combination, potentially diluting existing shareholders.
• The high interest rate of 10% increases the financial burden on PowerUp.

Risks

• The merger with Aspire Biopharma may not be completed, which could impact the repayment of the loan and the value of the shares issued to Blackstone.
• PowerUp may not be able to raise the required $5,000,000 in debt or equity, potentially triggering the earlier maturity date of the loan.
• The company's ability to repay the loan is dependent on the success of the merger and future financial performance.
• The loan agreement includes a waiver of claims against the trust account, which could limit the lender's recourse in case of default.

Future Outlook

The company is focused on completing the merger with Aspire Biopharma, and the loan is intended to support this effort. The company's future financial performance is dependent on the success of the merger and its ability to raise additional capital.

Management Comments

• There are no direct quotes from management in this document, but the company is actively working to complete the merger with Aspire Biopharma.

Industry Context

This announcement is typical for a SPAC (Special Purpose Acquisition Company) seeking to complete a business combination. The loan is a common method for SPACs to secure short-term funding to bridge the gap until the merger is finalized.

Comparison to Industry Standards

• The terms of the loan, including the 20% original issue discount and 10% exit fee, are relatively high, which may indicate a higher risk profile for PowerUp.
• The interest rate of 10% is also on the higher end compared to typical corporate loans, reflecting the risk associated with the company's current financial situation.
• The requirement to transfer shares to Blackstone upon the closing of the Business Combination is a common practice in SPAC transactions, but the specific terms (three shares per dollar loaned) are specific to this deal.
• The registration rights agreement is a standard provision in such transactions, ensuring that the lender can potentially liquidate its investment in the future.

Related Party Transactions

• The loan agreement with Blackstone Capital Advisors, Inc. is a related party transaction as Lance Friedman, Aspire Biopharma's Director of Investor Relations, controls Blackstone.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of shares to Blackstone.
• Creditors may be concerned about the company's ability to repay the loan.
• Employees may be affected by the outcome of the merger and the company's financial stability.

Next Steps

• PowerUp needs to complete the merger with Aspire Biopharma.
• PowerUp needs to raise at least $5,000,000 in debt or equity to avoid the earlier maturity date of the loan.
• PowerUp needs to register the shares issued to Blackstone with the SEC.

Key Dates

Keywords

PowerUp Acquisition Corp, Blackstone Capital Advisors, Aspire Biopharma, Merger, Loan Agreement, Promissory Note, Registration Rights, Business Combination, Capital Raise, SPAC